Osteoporosis – a current view of pharmacological prevention and treatment

Postmenopausal osteoporosis is the most common bone disease, associated with low bone mineral density (BMD) and pathological fractures which lead to significant morbidity. It is defined clinically by a BMD of 2.5 standard deviations or more below the young female adult mean (T-score =−2.5). Osteoporosis was a huge global problem both socially and economically – in the UK alone, in 2011 £6 million per day was spent on treatment and social care of the 230,000 osteoporotic fracture patients – and therefore viable preventative and therapeutic approaches are key to managing this problem within the aging population of today. One of the main issues surrounding the potential of osteoporosis management is diagnosing patients at risk before they develop a fracture. We discuss the current and future possibilities for identifying susceptible patients, from fracture risk assessment to shape modeling and in relation to the high heritability of osteoporosis now that a plethora of genes have been associated with low BMD and osteoporotic fracture. This review highlights the current therapeutics in clinical use (including bisphosphonates, anti-RANKL [receptor activator of NF-κB ligand], intermittent low dose parathyroid hormone, and strontium ranelate) and some of those in development (anti-sclerostin antibodies and cathepsin K inhibitors). By highlighting the intimate relationship between the activities of bone forming (osteoblasts) and bone-resorbing (osteoclasts) cells, we include an overview and comparison of the molecular mechanisms exploited in each therapy.

[1]  G. Mundy,et al.  Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.

[2]  M. Nevitt,et al.  Active Shape Modeling of the Hip in the Prediction of Incident Hip Fracture , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  D O Slosman,et al.  Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.

[4]  Steven Boonen,et al.  Testosterone and the Male Skeleton: A Dual Mode of Action , 2011, Journal of osteoporosis.

[5]  J. Jansen,et al.  Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies , 2009, Current medical research and opinion.

[6]  B. Rovin,et al.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2008, The New England journal of medicine.

[7]  P. Roberson,et al.  Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.

[8]  C. Cooper,et al.  Antidepressant medications and osteoporosis. , 2012, Bone.

[9]  G. Pescarmona,et al.  Teriparatide increases the maturation of circulating osteoblast precursors , 2012, Osteoporosis International.

[10]  Kozo Nakamura,et al.  Suppressive function of androgen receptor in bone resorption , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[12]  G. Gamble,et al.  Discrepancies in predicted fracture risk in elderly people , 2013, BMJ.

[13]  G. Siest,et al.  Segregation analysis and variance components analysis of bone mineral density in healthy families , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  D. Saxena,et al.  Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. , 2013, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[15]  P. Geusens,et al.  Osteopenia: A Diagnostic and Therapeutic Challenge , 2011, Current osteoporosis reports.

[16]  M. Rogers,et al.  Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  O. Fromigué,et al.  Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. , 2009, Journal of cellular and molecular medicine.

[18]  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[19]  A Hofman,et al.  Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.

[20]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Shlossman,et al.  Calcitonin effects on isolated bone cells , 1982, Calcified Tissue International.

[22]  S. Ortolani,et al.  Genetics of osteoporosis , 1994, Calcified Tissue International.

[23]  J Reeve,et al.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. , 1980, British medical journal.

[24]  T. Spinks,et al.  Periodic courses of human 1–34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis , 1987, European journal of clinical investigation.

[25]  M. Francis,et al.  Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. , 2007, Journal of musculoskeletal & neuronal interactions.

[26]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.

[27]  B. Gelb,et al.  Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.

[28]  R. Eastell,et al.  Osteoporosis in men: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[29]  T. Chambers,et al.  Calcitonin alters behaviour of isolated osteoclasts , 1982, The Journal of pathology.

[30]  J. Devogelaer,et al.  Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men , 2010, Current osteoporosis reports.

[31]  Rocky S Tuan,et al.  Concise Review: The Clinical Application of Mesenchymal Stem Cells for Musculoskeletal Regeneration: Current Status and Perspectives , 2012, Stem cells translational medicine.

[32]  Joanne L Welton,et al.  Monocytes and γδ T cells control the acute‐phase response to intravenous zoledronate: Insights from a phase IV safety trial , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  C. Christiansen,et al.  Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. , 2008, Current medical research and opinion.

[34]  K. Lam,et al.  Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass , 2012, Nature Medicine.

[35]  Eugene McCloskey,et al.  FRAX and its applications to clinical practice. , 2009, Bone.

[36]  L. Melton,et al.  The Unitary Model for Estrogen Deficiency and the Pathogenesis of Osteoporosis: Is a Revision Needed? , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[38]  J. Mönkkönen,et al.  The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. , 2001, Arthritis and rheumatism.

[39]  Kenji F. Tanaka,et al.  A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy Expenditure , 2009, Cell.

[40]  J. Hopper,et al.  Genetic determinants of bone mass in adults. A twin study. , 1987, The Journal of clinical investigation.

[41]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. LoRusso,et al.  Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases , 2002, Journal of clinical pharmacology.

[43]  Sharmila Majumdar,et al.  Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  O. Beirne,et al.  The relationship of denosumab pharmacology and osteonecrosis of the jaws. , 2012, Oral surgery, oral medicine, oral pathology and oral radiology.

[45]  D. Cocchi,et al.  Invited review: Dairy intake and bone health: a viewpoint from the state of the art. , 2011, Journal of dairy science.

[46]  E. Pieterman,et al.  Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. , 1999, Biochemical and biophysical research communications.

[47]  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. , 1997, Lancet.

[48]  H. Chao,et al.  Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. , 2008, Maturitas.

[49]  R. Parker,et al.  Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. , 2007, Maturitas.

[50]  U. P. S. T. Force Screening for osteoporosis: recommendation statement. , 2011 .

[51]  D P Fyhrie,et al.  In vivo trabecular microcracks in human vertebral bone. , 1996, Bone.

[52]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[53]  E. Brown,et al.  The Calcium-sensing Receptor Is Involved in Strontium Ranelate-induced Osteoclast Apoptosis , 2009, Journal of Biological Chemistry.

[54]  H. Sowa,et al.  Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis , 2013, Journal of Bone and Mineral Metabolism.

[55]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[56]  Carol Coupland,et al.  Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.

[57]  J. Nieves,et al.  Skeletal effects of nutrients and nutraceuticals, beyond calcium and vitamin D , 2013, Osteoporosis International.

[58]  J. Mönkkönen,et al.  Biochemical and molecular mechanisms of action of bisphosphonates. , 2011, Bone.

[59]  J. Reginster,et al.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.

[60]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[61]  T. Sugimoto,et al.  Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women , 2012, Osteoporosis International.

[62]  D. Hanley,et al.  Parathyroid hormone: regulation of synthesis and secretion. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[63]  Mark J Bolland,et al.  Evaluation of the FRAX and Garvan fracture risk calculators in older women , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[64]  O. Johnell,et al.  Requirements for DXA for the management of osteoporosis in Europe , 2005, Osteoporosis International.

[65]  R. Aspden,et al.  A method for assessment of the shape of the proximal femur and its relationship to osteoporotic hip fracture , 2004, Osteoporosis International.

[66]  Marcea Whitaker,et al.  Bisphosphonates for osteoporosis--where do we go from here? , 2012, The New England journal of medicine.

[67]  S. Perry,et al.  Screening postmenopausal women for fall and fracture prevention. , 2013, Journal of geriatric physical therapy.

[68]  N. Freemantle,et al.  Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis , 2012, Osteoporosis International.

[69]  F. Saltel,et al.  Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. , 2008, Bone.

[70]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[71]  J. Falgueyret,et al.  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.

[72]  B. Walsh,et al.  Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[73]  C C Glüer,et al.  Simple measurement of femoral geometry predicts hip fracture: The study of osteoporotic fractures , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[74]  P. Meunier,et al.  Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  C. Xian,et al.  Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling , 2013, Journal of cellular physiology.

[76]  E. Brown,et al.  Strontium Ranelate Decreases Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastic Differentiation In Vitro: Involvement of the Calcium-Sensing Receptor , 2010, Molecular Pharmacology.

[77]  Michael C. Nevitt,et al.  Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .

[78]  Alejandro F. Frangi,et al.  Hip fracture discrimination from dual-energy X-ray absorptiometry by statistical model registration. , 2012, Bone.

[79]  Robert Langer,et al.  First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip , 2012, Science Translational Medicine.

[80]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[81]  T. Einhorn,et al.  Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. , 2012, Bone.

[82]  L. Assael Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[83]  Steven Boonen,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[84]  Sheila J. Jones,et al.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[85]  R. Rizzoli Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis , 2010, Therapeutic advances in musculoskeletal disease.

[86]  J. Cauley,et al.  Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. , 2007, Bone.

[87]  Agnes Grünerbl,et al.  Trabecular Bone Analysis in CT and X-Ray Images of the Proximal Femur for the Assessment of Local Bone Quality , 2009, IEEE Transactions on Medical Imaging.

[88]  Guoyin Feng,et al.  Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β‐Catenin Signaling , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[89]  P. Yelick,et al.  Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[90]  E. Schwartz,et al.  Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[91]  L. Hocking,et al.  Bone remodelling at a glance , 2011, Journal of Cell Science.

[92]  H. Macdonald,et al.  Women with previous fragility fractures can be classified based on bone microarchitecture and finite element analysis measured with HR-pQCT , 2013, Osteoporosis International.

[93]  S. M. Arija,et al.  Biochemical Markers in Osteoporosis: Usefulness in Clinical Practice , 2012 .

[94]  D. Findlay,et al.  Calcitonin: Physiology or fantasy? , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[95]  N. D. Nguyen,et al.  Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks , 2008, Osteoporosis International.

[96]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[97]  C. Poulter,et al.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. , 2001, The Journal of pharmacology and experimental therapeutics.

[98]  J. Bilezikian,et al.  Sclerostin: Therapeutic Horizons Based Upon Its Actions , 2012, Current Osteoporosis Reports.

[99]  G. Bilbe,et al.  Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. , 1995, Biochemical and biophysical research communications.

[100]  O. Fromigué,et al.  Calcium sensing receptor‐dependent and receptor‐independent activation of osteoblast replication and survival by strontium ranelate , 2009 .

[101]  B. Clarke,et al.  Normal bone anatomy and physiology. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[102]  R. Marx,et al.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[103]  D. Reid,et al.  Nutrition and bone: is there more to it than just calcium and vitamin D? , 2001, QJM : monthly journal of the Association of Physicians.

[104]  E. Andrews,et al.  The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[105]  O. Bruyère,et al.  Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club , 2011, Osteoporosis International.

[106]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[107]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[108]  J. Reginster,et al.  Adverse drug reactions to osteoporosis treatments , 2011, Expert review of clinical pharmacology.

[109]  J. Pasco,et al.  The population burden of fractures originates in women with osteopenia, not osteoporosis , 2006, Osteoporosis International.

[110]  O. Kennedy,et al.  Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. , 2012, Bone.

[111]  D. D. de Luis,et al.  Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women , 2010, Journal of osteoporosis.

[112]  J. Caverzasio Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. , 2008, Bone.

[113]  J. Kanis,et al.  Pitfalls in the external validation of FRAX , 2012, Osteoporosis International.

[114]  K. Ng Potential role of odanacatib in the treatment of osteoporosis , 2012, Clinical interventions in aging.

[115]  Y. Isogai,et al.  Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). , 2012, The Journal of toxicological sciences.

[116]  E. Torres,et al.  Actualización sobre la determinación de marcadores de remodelado óseo , 2003 .

[117]  R. Aspden,et al.  Can we improve the prediction of hip fracture by assessing bone structure using shape and appearance modelling? , 2013, Bone.

[118]  Bjarni V. Halldórsson,et al.  New sequence variants associated with bone mineral density , 2009, Nature Genetics.

[119]  Hang Lee,et al.  Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.

[120]  C. Moran,et al.  Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. , 2012, The Journal of bone and joint surgery. British volume.

[121]  E. Posvar,et al.  Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[122]  S. Boonen,et al.  Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. , 2008, The Journal of clinical endocrinology and metabolism.

[123]  M. Rogers,et al.  The regulation of osteoclast function and bone resorption by small GTPases , 2011, Small GTPases.

[124]  R. Russell,et al.  Diphosphonates and Page's disease of bone. , 1971, Lancet.

[125]  R. Burge,et al.  Fractures in women treated with raloxifene or alendronate: a retrospective database analysis , 2013, BMC Women's Health.

[126]  P. Fratzl,et al.  Microcracks and Osteoclast Resorption Activity In Vitro , 2012, Calcified Tissue International.

[127]  K. Walker-Bone Recognizing and treating secondary osteoporosis , 2012, Nature Reviews Rheumatology.

[128]  J. Riancho,et al.  Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates , 2010, The Pharmacogenomics Journal.

[129]  D. Kiel,et al.  Risk Factors for Longitudinal Bone Loss in Elderly Men and Women: The Framingham Osteoporosis Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[130]  Ernest K. Poku,et al.  Developing Novel Prognostic Biomarkers for Multivariate Fracture Risk Prediction Algorithms , 2012, Calcified Tissue International.

[131]  M. Bouxsein,et al.  Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[132]  B. Gertz,et al.  Clinical pharmacology of alendronate sodium , 2005, Osteoporosis International.

[133]  Scott M Smith,et al.  Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes , 2012, Proceedings of the National Academy of Sciences.